The PennZone

  • Home
  • Non-profit
  • Technology
  • Education
  • Business
  • Construction
  • Entertainment
  • Health
  • Software

ExpressCells to Present in BIO Start-Up Stadium Next Week
The PennZone/10070540

Trending...
  • Calvetta Phair, CEO America's Workforce Solution, LLC Assessed "Awardable" for Department of War work in the CDAO's Tradewinds Solutions Marketplace
  • Creative Investment Research Analysis Finds Slower GDP Growth, Rising Inflation
  • Christian Apocalyptic Thriller Explores Biblical Prophecy, Global Technology, & the Rise of the Ant
Company is one of 30 selected for prestigious competition. During BIO Digital Week, attendees can watch timely, on-demand pitches and meet with ExpressCells via BIO's One-on-One Partnering.

PHILADELPHIA - PennZone -- ExpressCells, Inc. (ExpressCells), a privately-owned genetic engineering company that creates knock-in cell lines for drug discovery, will be one of the finalists presenting in the Start-Up Stadium during BIO Digital Week.

"We are honored to be selected by the judges as one of the finalists for Start-Up Stadium. We hope that all BIO Digital Week attendees view our presentation, which will be available on demand via the meeting platform."

Start-Up Stadium provides an exciting and interactive experience where key stakeholders of the early-stage life science community, investors, and strategic partners provide feedback and judge 6 minute pitches presented by start-up biotech companies. During BIO Digital Week, attendees can watch ExpressCells' pitch on-demand and meet with the company via BIO's One-on-One Partnering.

More on The PennZone
  • AI Is Making It Easier for API-First Platforms to Connect, Partner, Reach Customers, and Grow Revenue Faster
  • 2026 Editorial Freelancers Association Conference Focuses on Building Sustainable Careers
  • Eichelberger Performing Arts Center Announces Fall 2026 Performance Lineup
  • netElastic Powers LigaT's High-Performance Broadband Expansion and IPv6 Modernization in Portugal
  • IWS Press Expands Best-Selling Classic Wealth Library with Seventh Book

"ExpressCells is excited to be part of BIO Digital Week," Mr. Handel continued. "We hope to gain valuable feedback and to meet with both potential customers and potential investors.

About ExpressCells

ExpressCells is a private biotechnology company based in Philadelphia, PA. Its propriety genome editing technology, in combination with CRISPR/Cas9, creates advanced, knock-in cell line up to 75% faster than older processes. This technology allows ExpressCells to insert up to three genes into the same cell line.

ExpressCells' first knock-in cell lines code for bioluminescent and fluorescent proteins. These allow scientists to more see the results of their experiments in real time. ExpressCells sells both custom cell lines—each designed to meet the specific requirements of an individual scientist—and catalog cell lines. For more information, visit www.xpresscells.com.

Contact
Matthew Handel
***@xpresscells.com
+1 (484) 483-6759


Source: ExpressCells, Inc.

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Boston Industrial Solutions Launches Natron® 348 UV Inkjet Ink for Epson S3200 Print Heads
  • Heritage at South Brunswick Unveils Luxury Resort-Style Amenities Designed for Every Generation
  • CAPHRA warns push for ASEAN vape ban ignores science
  • Your Mortgage Toolbox Launches Free Mortgage Calculators That Show the Real Monthly Payment and Cash Needed to Close
  • ENTOUCH Recognized on Inc.'s 2026 Best Workplaces List for the Third Year Running
  • P-Wave Classics Opens Pre-Orders for Volume II of Robert Bage's Hermsprong
  • Cabinetworks Group announces recipient of 2025 Plant of the Year
  • Honesdale Painters Launch Season With Act of Community Kindness
  • Tuckwell Machinery Launches New Range of Woodworking Machinery
  • A Brave Little Hero with Four Paws
  • Pittsburgh-Area Author Erica L. Day Releases HER, a Christian Second-Chance Romance and Its Own Comp
  • Revenue Optics Expands Its Private Equity Practice as Sponsors Move Inside Sales to the Center of Distribution Value Creation
  • Ecuador Freedom Launches First Scheduled Motorcycle Tour of Northern Peru's Lost Kingdoms
  • Lineus Medical Completes Financial Restructuring with KMF Investments- Launching a New Era for SafeBreak
  • Neuro Recovery Institute Showcases Emerging Immersive Neuro-Rehabilitation Technology at Clinical Innovation Open House
  • Community, Conservation & Waterwise Inspiration Bloom on June 6
  • Industrial and systems engineers celebrate key leaders in the field at IISE Annual Conference
  • Cosanostra Miami Rises as the Best Latin Nightclub in Miami in Under Two Years From its Opening
  • CCHR Leader's 50-Year Fight for Psychiatric Drug Victims Gains National Momentum
  • Endless Mountain Music Festival Celebrates 21st Season with America250-Inspired Lineup

Popular on PennZone

  • People & Stories/Gente y Cuentos Welcomes Two New Trustees as Organization Enters 54th Year and Expands Community Reach
  • Assymetrix Launches the Deepest Independent Prediction Market Data API
  • Resident Inspect Joins Property Meld Nexus Network with API Integration
  • RAS AP Consulting Advances to RFP Stage in Heidelberg Materials' SAP Vendor & Customer Master Data Modernization Initiative
  • New Home of the Month: Spacious Luxury Meets Modern Design in The Bristol at Heritage at Manalapan
  • Expert E-Bike Safety Advocate Issues Urgent Warning Following Recent Southern California Fatalities
  • CCHR: 'Plant-Based' Psychedelics Push Masks Synthetic Drugs and Billion-Dollar Profits
  • "I'm Sicka Church Too: Give Me Kingdom!" Ignites a Powerful Call for Healing and Truth
  • Umbrella Becomes First FinOps Platform to Support AWS Billing Transfer Onboarding
  • Veikkaus Appoints New CFO as Finland's Gambling Monopoly Braces for Breakup

Similar on PennZone

  • Entering the $69 Billion Animal Health Market, Delivering Record Growth, AI-Driven Healthcare Innovation, and Targeting $200 Million Revenue by 2029
  • FDA-Cleared AI Neuropsychiatry Platform, Million-Dose Ketamine Manufacturing and Presidential Psychedelic Initiative Drive Growing Momentum for NRXP
  • Accelerating Toward Commercialization as FDA Momentum, AI Neurotherapy & Manufacturing Expansion Drive Multi-Catalyst Growth Story; N A S D A Q: NRXP
  • Philadelphia Scientist Roohid Parast Advances IBD Research at Johnson & Johnson
  • Medical Experts Highlight the Importance of Second Opinions in Death Investigations
  • NRx Pharmaceuticals (N A S D A Q: NRXP) Accelerates Into National Spotlight as Manufacturing Launch, Federal Policy & AI-Driven Breakthroughs Converge
  • More Life Summit 2026 Announces Gary Brecka & Mr. Olympia Derek Lunsford as First Speakers for Miami Event
  • Presidential Acceleration of Psychedelic Therapies Enters a Defining Moment as Federal Policy, FDA Alignment & Breakthrough Neurotechnology Converge
  • Dual-Engine Growth Strategy Unleashed Targeting a $9.1B Market and the Exploding AI Biotech Revolution: KALA BIO (N A S D A Q: KALA)
  • AI-Driven Neurotechnology Expansion as FDA Path Clears and New Defense Initiative Emerges for NRx Pharmaceuticals (N A S D A Q: NRXP)
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us